According to SCYNEXIS's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.417562. At the end of 2023 the company had a P/S ratio of 0.5921.
Year | P/S ratio | Change |
---|---|---|
2023 | 0.5921 | -94.08% |
2022 | 10.0 | -9.84% |
2021 | 11.1 | |
2020 | N/A | -100% |
2019 | 733 | 711.62% |
2018 | 90.3 | -65.12% |
2017 | 259 | -13.42% |
2016 | 299 | -11.03% |
2015 | 336 | 3905.94% |
2014 | 8.39 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Galmed Pharmaceuticals
GLMD | N/A | N/A | ๐ฎ๐ฑ Israel |
Catalyst Pharmaceuticals CPRX | 4.41 | 956.79% | ๐บ๐ธ USA |
Catalent CTLT | 2.47 | 491.73% | ๐บ๐ธ USA |
KemPharm KMPH | 19.2 | 4,490.79% | ๐บ๐ธ USA |